4D Molecular Therapeutics, Inc. (FDMT) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-07-14

4D Molecular Therapeutics, Inc. (FDMT) has filed 12 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-14. 3 Form 8-K material event filings were reported by FDMT in the last 90 days. 6 Form 144 notices of proposed sale were filed for FDMT stock. InsiderAlpha tracks every FDMT SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About 4D Molecular Therapeutics, Inc. (FDMT)

SIC classification	Biological Products, (No Diagnostic Substances) (SIC 2836)
SEC CIK	0001650648

90-Day SEC Filing Activity

Form 4 filings (90d)	12
Form 8-K filings (90d)	3
Form 144 notices (90d)	6
Latest Form 4 filing	2026-07-14

Recent FDMT Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-07-10	Kirn David	See Remarks	S — Open-market sale [10b5-1]	15.3K	$12.01	$184K	SEC
2026-07-10	Kirn David	See Remarks	S — Open-market sale [10b5-1]	442	$12.84	$6K	SEC
2026-07-09	Kirn David	See Remarks	S — Open-market sale [10b5-1]	42.6K	$12.87	$548K	SEC
2026-06-30	Bizily Scott	Chief Legal Officer	S — Open-market sale	6.6K	$14.00	$92K	SEC
2026-06-30	Bizily Scott	Chief Legal Officer	M — Option exercise	814	$4.14	$3K	SEC
2026-06-30	Bizily Scott	Chief Legal Officer	M — Option exercise	5.8K	$6.49	$37K	SEC
2026-06-23	Bizily Scott	Chief Legal Officer	M — Option exercise	9.8K	$4.14	$41K	SEC
2026-06-23	Bizily Scott	Chief Legal Officer	S — Open-market sale	9.8K	$12.00	$118K	SEC
2026-06-22	Kirn David	See Remarks	S — Open-market sale	114.7K	$10.47	$1.20M	SEC
2026-06-01	Kirn David	See Remarks	S — Open-market sale	1.9K	$10.02	$19K	SEC
2026-03-20	Gupta Ashoo	VP, Finance and Controller	M — Option exercise	221	—	—	SEC
2026-03-20	Gupta Ashoo	VP, Finance and Controller	S — Open-market sale	310	$8.61	$3K	SEC
2026-03-20	Gupta Ashoo	VP, Finance and Controller	S — Open-market sale	80	$8.61	$689	SEC
2026-03-20	Gupta Ashoo	VP, Finance and Controller	M — Option exercise	865	—	—	SEC
2025-12-20	Gupta Ashoo	VP, Finance and Controller	M — Option exercise	220	—	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for 4D Molecular Therapeutics, Inc. (FDMT). Updated in real time as new filings are submitted to the SEC.

Most-Active FDMT Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Bizily Scott	8	$291K
Kirn David	5	$1.96M
MILLIGAN JOHN F	1	—
Miller-Rich Nancy	1	—
THEUER CHARLES	1	—

Recent FDMT Form 8-K Material Events

2026-06-29 — Item 1.01, 2.03 [SEC]
2026-06-22 — Item 5.07 [SEC]
2026-05-07 — Item 2.02, 9.01 [SEC]
2026-03-30 — Item 5.02 · Leadership · neutral [SEC]
4D Molecular Therapeutics appointed Kristian Humer as Principal Accounting Officer effective March 25, 2026. Humer, who has served as CFO since November 2025, brings extensive biotechnology and investment banking experience. The previous Principal Accounting Officer, Ashoo Gupta,
2026-03-18 — Item 2.02, 9.01 · Earnings · neutral [SEC]
4D Molecular Therapeutics announced its full year 2025 financial results on March 18, 2026, along with operational highlights and expected upcoming milestones. The filing provides standard financial reporting without explicit beat/miss language or guidance changes.

Recent FDMT Form 144 Notices of Proposed Sale

2026-07-10 — — [SEC]
2026-07-09 — — [SEC]
2026-06-30 — — [SEC]

Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.

Recent Insider Filings

2026-07-14 — Kirn David (See Remarks)
2026-07-02 — Bizily Scott (Chief Legal Officer)
2026-06-25 — Bizily Scott (Chief Legal Officer)
2026-06-23 — Kirn David (See Remarks)
2026-06-18 — Tomasello Shawn (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in FDMT insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

FDMT Insider Trading — FAQ

What is the latest insider trade for FDMT?: 4D Molecular Therapeutics, Inc. (FDMT) had 12 insider filings in the last 90 days, with the most recent on 2026-07-14. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying FDMT stock?: 0 insider purchases of FDMT were filed in the last 90 days.
How many insiders are selling FDMT stock?: 0 insider sales of FDMT were filed in the last 90 days.
Where can I see FDMT SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every FDMT SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live FDMT dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.